Vimarsana
Biggest News Aggregation in the World

Page 14 - Hartmutj Ehrlich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hartmutj Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hartmutj Ehrlich Today - Breaking & Trending Today

Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative coli - Vimarsana News

Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative coli

Search jobs 24-May-2021 Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 DGAP-News: ABIVAX / Key word(s): Study results 24.05.2021 / 18:30 The issuer is solely responsible for the content of this announcement. Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 Primary endpoint (statistically significant reduction of Modified Mayo Score [1]) was met with once-daily ABX464 (25m...

Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy - Vimarsana News

Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy

Press release content from Accesswire. The AP news staff was not involved in its creation. Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy March 5, 2021 GMT The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients Lower than expected rate (10.1%) of progression to severe disease or death with no difference between ABX464 and placebo groups Decision has no impact on ABX464 development in chronic inflammatory indications ABX464 top-line clinical data expected in ...

Source: apnews.com
Investegate |ABIVAX Announcements | ABIVAX: Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy - Vimarsana News

Investegate |ABIVAX Announcements | ABIVAX: Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy

ABIVAX Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy DGAP-News: ABIVAX / Key word(s): Study Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy 05.03.2021 / 20:00 Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial  due to lack of efficacy The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients Lower than expected rate (10.1%) of progression to severe disea...

Investegate |ABIVAX Announcements | ABIVAX: Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology' - Vimarsana News

Investegate |ABIVAX Announcements | ABIVAX: Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology'

ABIVAX Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology' DGAP-News: ABIVAX / Key word(s): Miscellaneous Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology' 03.03.2021 / 18:30 The issuer is solely responsible for the content of this announcement. Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal "Gastroenterology" Peer-revie...

Abivax Appoints Dr. Sophie Biguenet, M.D., as Chief Medical Officer - Vimarsana News

Abivax Appoints Dr. Sophie Biguenet, M.D., as Chief Medical Officer

Press release content from Accesswire. The AP news staff was not involved in its creation.

Source: apnews.com